FBIO — Fortress Biotech Cashflow Statement
0.000.00%
Last trade - 00:00
- $48.25m
- $1.93m
- $84.51m
- 16
- 40
- 33
- 20
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -102 | -103 | -165 | -214 | -154 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 8.44 | 20.4 | 6.81 | 27.8 | 32.5 |
Discontinued Operations | |||||
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -4.84 | -4.78 | 36.4 | -0.715 | -12.5 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -95 | -83.7 | -117 | -179 | -128 |
Capital Expenditures | -4.75 | -3.13 | -4.97 | -2.71 | -5.06 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 24.8 | -4.04 | 45.5 | -20.2 | 2.96 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 20.1 | -7.16 | 40.5 | -22.9 | -2.1 |
Financing Cash Flow Items | 76.1 | 41.5 | 119 | 14.2 | 4.59 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 147 | 172 | 149 | 75.3 | 32.7 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 71.8 | 81.6 | 73 | -127 | -97.6 |